Evidence map›Paper›PMID 26137300›Full record

ArticleUnited European gastroenterology journal2015

Buspirone, a new drug for the management of patients with ineffective esophageal motility?

Charlotte Scheerens, Jan Tack, Nathalie Rommel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Long-term Prognosis and Prognostic Factors in Ineffective Esophageal Motility.Journal of neurogastroenterology and motility · 2025
    Article
  3. Article
  4. Review
  5. Management of scleroderma gastrointestinal disease: Lights and shadows.Journal of scleroderma and related disorders · 2022
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Understanding the Chicago Classification: From Tracings to Patients.Journal of neurogastroenterology and motility · 2017
    Review
  15. Review
  16. Primary Esophageal Motility Disorders: Beyond Achalasia.International journal of molecular sciences · 2017
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Charlotte ScheerensKU Leuven -- University of Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, Leuven, Belgium ; KU Leuven -- University of Leuven, Research Group Experimental Otorhinolaryngology (ExpORL), Department of Neurosciences, Leuven, Belgium.
Jan TackKU Leuven -- University of Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, Leuven, Belgium ; UZ Leuven -- University Hospitals Leuven, Neurogastroenterology and Motility Clinic, Department of Internal Medicine, Division of Gastroenterology, Leuven, Belgium.
Nathalie RommelKU Leuven -- University of Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, Leuven, Belgium ; KU Leuven -- University of Leuven, Research Group Experimental Otorhinolaryngology (ExpORL), Department of Neurosciences, Leuven, Belgium ; UZ Leuven -- University Hospitals Leuven, Neurogastroenterology and Motility Clinic, Department of Internal Medicine, Division of Gastroenterology, Leuven, Belgium.
Universitair Ziekenhuis Leuven · BEKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ineffective esophageal motility (IEM) is the most frequently encountered esophageal motility disorder. Patients may present with a variety of symptoms, such as dysphagia, heartburn, odynophagia, and regurgitation. Over the past years, the landscape of esophageal motility testing has been revolutionized; however, our current treatment options for IEM still remain limited. Previous studies have suggested that buspirone, a serotonin receptor agonist, enhances esophageal peristalsis and lower esophageal sphincter (LES) function. Recent work provides the first evidence that buspirone may influence LES resting pressure in patients with systemic sclerosis. Future research should evaluate whether the beneficial effects of buspirone also apply to the broad clinical entity of esophageal dysphagia patients with IEM.

Indexed as

5-HT1ABuspironeesophageal high-resolution manometryesophagusineffective esophageal motilitysystemic sclerosis

Identifiers

PMID26137300
PMCPMC4480541
OpenAlexW1962324575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.